What Is Sermorelin? A Research Overview

Sermorelin is a synthetic 29-amino-acid peptide analog of growth-hormone-releasing hormone (GHRH 1–29), studied in preclinical and clinical research as a growth-hormone-releasing factor that acts on the pituitary GHRH receptor. It corresponds to the first 29 amino acids of native human GHRH — the shortest fragment retaining the full biological activity of the parent hormone. This article is educational and intended for research audiences only; sermorelin research materials are sold strictly for research use only (RUO) and are not for human or veterinary use.

Quick facts

• Class: GHRH(1–29) analog (growth-hormone-releasing factor)
• Structure: synthetic 29-amino-acid peptide; the N-terminal fragment of human GHRH
• Research focus: GH / IGF-1 axis research and GHRH-receptor signaling
• Molecular target: growth-hormone-releasing hormone receptor (GHRH-R), a Class B GPCR

What is sermorelin?

Sermorelin is a peptide consisting of the first 29 amino acids of native human GHRH, which is itself a 44-amino-acid hypothalamic peptide. Because biological activity is concentrated in the N-terminal region, this truncated GHRH(1–29) fragment is frequently described as the shortest synthetic peptide that retains the full activity of GHRH. In research models it is studied as a tool for probing the hypothalamic–pituitary growth-hormone axis.

What does the research show?

Sermorelin has been characterized across mechanistic and clinical literature. A review in BioDrugs describes it as the shortest synthetic peptide with full biological activity of GHRH and summarizes its investigation as a relatively specific provocative agent for evaluating growth-hormone secretion [1]. In a multicenter study of growth-hormone-deficient children in the Journal of Clinical Endocrinology & Metabolism, once-daily subcutaneous GHRH(1–29) was associated with an increase in mean height velocity from roughly 4.1 cm/yr at baseline to 8.0 and 7.2 cm/yr at 6 and 12 months [2]. These findings are presented strictly as historical research data and are not claims about outcomes in readers.

Mechanisms studied in the lab

• GHRH-receptor agonism: sermorelin binds GHRH-R, a Class B G-protein-coupled receptor on pituitary somatotrophs [3].
• cAMP signaling: receptor activation couples to adenylate cyclase, raising intracellular cAMP and activating protein kinase A (PKA), which modulates GH gene expression [3].
• GH release: downstream calcium influx is associated with secretion of stored growth hormone in research models [3].
• Pulsatile pattern: as a releasing factor upstream of GH, it is studied for its effect on endogenous, pulsatile GH secretion rather than direct GH replacement [1].

How sermorelin compares to other GHRH analogs

Sermorelin is the prototypical GHRH(1–29) analog. CJC-1295 is a modified GHRH analog engineered with amino-acid substitutions (and, in the DAC form, a binding moiety) intended in research to extend half-life. Tesamorelin is a stabilized GHRH analog with an N-terminal modification. All three are studied as GHRH-receptor agonists on the GH/IGF-1 axis; they differ primarily in structural modifications and reported pharmacokinetics. None of these comparisons imply suitability for human use.

Research status

Sermorelin does have a documented history of regulatory approval in human medicine, including diagnostic and pediatric growth-hormone-deficiency contexts, before the branded products were later withdrawn from the U.S. market as a manufacturer business decision; U.S. regulators subsequently determined the product was not withdrawn for reasons of safety or effectiveness. That history is stated here as factual background only. The research materials referenced on this site are supplied strictly for research use only — not drugs, not for human or veterinary use.

Related research peptides

Researchers studying the GH/IGF-1 axis often work with adjacent GHRH analogs and secretagogues. Explore related compounds — including CJC-1295, Tesamorelin, and Ipamorelin — across the full research peptide catalog. Bolt Peptide does not currently offer sermorelin; this article is provided for educational reference.

FAQ

Is sermorelin the same as GHRH? Sermorelin is GHRH(1–29) — the first 29 amino acids of the full 44-amino-acid GHRH peptide, reproducing its biologically active N-terminal region.

How does sermorelin differ from a secretagogue like ipamorelin? Sermorelin acts at the GHRH receptor, whereas ghrelin-mimetic secretagogues such as ipamorelin act at the GH-secretagogue receptor (GHSR). They engage distinct receptors upstream of GH release.

Can I buy sermorelin for human use? No. Bolt Peptide does not sell sermorelin, and any research peptide it offers is supplied strictly for research use only — not for human or veterinary use.

References

1. Prakash A, Goa KL. Sermorelin: a review. BioDrugs. 1999.
2. Thorner M, et al. Once-daily GHRH(1-29) accelerates growth in GH-deficient children (Geref study). J Clin Endocrinol Metab. 1996.
3. Halmos G, et al. GHRH receptor and its signaling. Rev Endocr Metab Disord. 2025.

For research use only. Not for human or veterinary use. Statements have not been evaluated by the FDA.